Concomitant use of blinatumomab and donor lymphocyte infusion for mixed-phenotype acute leukemia: A case report with literature review

Seren Durer, Ceren Durer, Madeeha Shafqat, Isin Yagmur Comba, Saad Malik, Warda Faridi, Shehroz Aslam, Awais Ijaz, Muhammad Junaid Tariq, Muhammad Asad Fraz, Muhammad Usman, Ali Y. Khan, Ali McBride, Faiz - Anwer

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Blinatumomab and donor lymphocyte infusion (DLI) combination is a promising cancer therapy, whereby blinatumomab might achieve an initial reduction in leukemic-cell burden using T cells, and after tumor clearance, DLI can potentially stimulate the donor immune system to achieve longer lasting remission. Here, we present a 51-year-old female with mixed phenotype acute leukemia who had a hematologic relapse 3 months after she received total body irradiation-based myeloablative allogeneic hematopoietic stem cell transplantation from an unrelated human leukocyte antigen matched (10/10) donor and achieved complete remission with minimal residual disease negativity by multi-parameter flow cytometry using the combination of blinatumomab and DLI. To the best of our knowledge, this is the first report to describe the use of blinatumomab and DLI combination therapy in the treatment of B/myeloid mixed phenotype acute leukemia.

Original languageEnglish (US)
Pages (from-to)373-378
Number of pages6
JournalImmunotherapy
Volume11
Issue number5
DOIs
StatePublished - Apr 1 2019
Externally publishedYes

Fingerprint

Leukemia
Lymphocytes
Phenotype
Whole-Body Irradiation
Hematopoietic Stem Cell Transplantation
Residual Neoplasm
HLA Antigens
Immune System
Neoplasms
Flow Cytometry
Therapeutics
T-Lymphocytes
Recurrence
blinatumomab

Keywords

  • acute leukemia
  • B/myeloid subtype
  • biphenotypic leukemia
  • bispecific T-cell engager
  • blinatumomab
  • CD19
  • donor lymphocyte infusion
  • immunotherapy
  • mixed-phenotype acute leukemia
  • MPAL

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

Concomitant use of blinatumomab and donor lymphocyte infusion for mixed-phenotype acute leukemia : A case report with literature review. / Durer, Seren; Durer, Ceren; Shafqat, Madeeha; Comba, Isin Yagmur; Malik, Saad; Faridi, Warda; Aslam, Shehroz; Ijaz, Awais; Tariq, Muhammad Junaid; Fraz, Muhammad Asad; Usman, Muhammad; Khan, Ali Y.; McBride, Ali; Anwer, Faiz -.

In: Immunotherapy, Vol. 11, No. 5, 01.04.2019, p. 373-378.

Research output: Contribution to journalReview article

Durer, S, Durer, C, Shafqat, M, Comba, IY, Malik, S, Faridi, W, Aslam, S, Ijaz, A, Tariq, MJ, Fraz, MA, Usman, M, Khan, AY, McBride, A & Anwer, F 2019, 'Concomitant use of blinatumomab and donor lymphocyte infusion for mixed-phenotype acute leukemia: A case report with literature review', Immunotherapy, vol. 11, no. 5, pp. 373-378. https://doi.org/10.2217/imt-2018-0104
Durer, Seren ; Durer, Ceren ; Shafqat, Madeeha ; Comba, Isin Yagmur ; Malik, Saad ; Faridi, Warda ; Aslam, Shehroz ; Ijaz, Awais ; Tariq, Muhammad Junaid ; Fraz, Muhammad Asad ; Usman, Muhammad ; Khan, Ali Y. ; McBride, Ali ; Anwer, Faiz -. / Concomitant use of blinatumomab and donor lymphocyte infusion for mixed-phenotype acute leukemia : A case report with literature review. In: Immunotherapy. 2019 ; Vol. 11, No. 5. pp. 373-378.
@article{a6151fe81db14d53ba2b892c925f1c41,
title = "Concomitant use of blinatumomab and donor lymphocyte infusion for mixed-phenotype acute leukemia: A case report with literature review",
abstract = "Blinatumomab and donor lymphocyte infusion (DLI) combination is a promising cancer therapy, whereby blinatumomab might achieve an initial reduction in leukemic-cell burden using T cells, and after tumor clearance, DLI can potentially stimulate the donor immune system to achieve longer lasting remission. Here, we present a 51-year-old female with mixed phenotype acute leukemia who had a hematologic relapse 3 months after she received total body irradiation-based myeloablative allogeneic hematopoietic stem cell transplantation from an unrelated human leukocyte antigen matched (10/10) donor and achieved complete remission with minimal residual disease negativity by multi-parameter flow cytometry using the combination of blinatumomab and DLI. To the best of our knowledge, this is the first report to describe the use of blinatumomab and DLI combination therapy in the treatment of B/myeloid mixed phenotype acute leukemia.",
keywords = "acute leukemia, B/myeloid subtype, biphenotypic leukemia, bispecific T-cell engager, blinatumomab, CD19, donor lymphocyte infusion, immunotherapy, mixed-phenotype acute leukemia, MPAL",
author = "Seren Durer and Ceren Durer and Madeeha Shafqat and Comba, {Isin Yagmur} and Saad Malik and Warda Faridi and Shehroz Aslam and Awais Ijaz and Tariq, {Muhammad Junaid} and Fraz, {Muhammad Asad} and Muhammad Usman and Khan, {Ali Y.} and Ali McBride and Anwer, {Faiz -}",
year = "2019",
month = "4",
day = "1",
doi = "10.2217/imt-2018-0104",
language = "English (US)",
volume = "11",
pages = "373--378",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "5",

}

TY - JOUR

T1 - Concomitant use of blinatumomab and donor lymphocyte infusion for mixed-phenotype acute leukemia

T2 - A case report with literature review

AU - Durer, Seren

AU - Durer, Ceren

AU - Shafqat, Madeeha

AU - Comba, Isin Yagmur

AU - Malik, Saad

AU - Faridi, Warda

AU - Aslam, Shehroz

AU - Ijaz, Awais

AU - Tariq, Muhammad Junaid

AU - Fraz, Muhammad Asad

AU - Usman, Muhammad

AU - Khan, Ali Y.

AU - McBride, Ali

AU - Anwer, Faiz -

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Blinatumomab and donor lymphocyte infusion (DLI) combination is a promising cancer therapy, whereby blinatumomab might achieve an initial reduction in leukemic-cell burden using T cells, and after tumor clearance, DLI can potentially stimulate the donor immune system to achieve longer lasting remission. Here, we present a 51-year-old female with mixed phenotype acute leukemia who had a hematologic relapse 3 months after she received total body irradiation-based myeloablative allogeneic hematopoietic stem cell transplantation from an unrelated human leukocyte antigen matched (10/10) donor and achieved complete remission with minimal residual disease negativity by multi-parameter flow cytometry using the combination of blinatumomab and DLI. To the best of our knowledge, this is the first report to describe the use of blinatumomab and DLI combination therapy in the treatment of B/myeloid mixed phenotype acute leukemia.

AB - Blinatumomab and donor lymphocyte infusion (DLI) combination is a promising cancer therapy, whereby blinatumomab might achieve an initial reduction in leukemic-cell burden using T cells, and after tumor clearance, DLI can potentially stimulate the donor immune system to achieve longer lasting remission. Here, we present a 51-year-old female with mixed phenotype acute leukemia who had a hematologic relapse 3 months after she received total body irradiation-based myeloablative allogeneic hematopoietic stem cell transplantation from an unrelated human leukocyte antigen matched (10/10) donor and achieved complete remission with minimal residual disease negativity by multi-parameter flow cytometry using the combination of blinatumomab and DLI. To the best of our knowledge, this is the first report to describe the use of blinatumomab and DLI combination therapy in the treatment of B/myeloid mixed phenotype acute leukemia.

KW - acute leukemia

KW - B/myeloid subtype

KW - biphenotypic leukemia

KW - bispecific T-cell engager

KW - blinatumomab

KW - CD19

KW - donor lymphocyte infusion

KW - immunotherapy

KW - mixed-phenotype acute leukemia

KW - MPAL

UR - http://www.scopus.com/inward/record.url?scp=85061998725&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061998725&partnerID=8YFLogxK

U2 - 10.2217/imt-2018-0104

DO - 10.2217/imt-2018-0104

M3 - Review article

C2 - 30786841

AN - SCOPUS:85061998725

VL - 11

SP - 373

EP - 378

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 5

ER -